Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843875 | 0.82 | IKBKB (0.49) | IKBKBCYP1A2CYP3A4CYP2C9KDM4E | |
| SCHEMBL3592428 | 0.70 | PTGS1 (0.41) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28178505 | 0.69 | IKBKB (0.36) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4973860 | 0.69 | IKBKB (0.55) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2313705 | 0.68 | IKBKB (0.77) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4091841 | 0.68 | IKBKB (1.00) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1852196 | 0.68 | MYC (0.61) | CHUKCYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL1724239 | 0.67 | IKBKB (1.00) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5157995 | 0.66 | — | — | |
| SCHEMBL3325856 | 0.66 | IKBKB (0.38) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105541866-B | 2 (4 fluorophenyl) 7 H thiophene [3 ', 2 ':4,5] the ketone heterocyclic compound of pyrimidine [6,1 b] quinazoline 7 and its synthetic method | 山东益康药业股份有限公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-105541866-A | 2-(4-fluorophenyl)-7-H-thiophene[3minute,2minute:4,5]pyrimidine[6,1-b]quinazoline-7-keto heterocyclic compound and synthetic method thereof | Shandong yikang pharmaceutical co ltd | 2016-05-04 | — | — | CN | disclosed |
| CN-105541865-A | 2,3,5-substituted imidazole[1,2-c]-thiophene[2,3-e]-7(8H)keto heterocyclic compound and synthetic method thereof | Shandong yikang pharmaceutical co ltd | 2016-05-04 | — | — | CN | disclosed |
| CN-105481879-A | Imidazole[1,2-c]-thiophene[2,3-e]pyrimidine-7(8H)ketone heterocyclic compound and synthesis method thereof | Shandong yikang pharmaceutical co ltd | 2016-04-13 | — | — | CN | disclosed |
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| CN-101500575-A | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMA (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2043654-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1597247-B1 | SUBSTITUTED 3-(BENZOYLUREIDO)-THIOPHENE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007146284-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
| US-7196114-B2 | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| EP-1054887-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1597247-A1 | SUBSTITUTED 3-(BENZOYLUREIDO)-THIOPHENE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040198742-A1 | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| WO-2004072060-A1 | SUBSTITUTED 3-(BENZOYLUREIDO)-THIOPHENE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| US-6583154-B1 | Neuropeptide Y antagonist; pyrrolo-(3,2-b)pyridines and pyrrolo-(3,2-d)pyrimidines | AMGEN INC. | 2003-06-24 | — | — | US | disclosed |
| US-6187777-B1 | PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES; NEUROPEPTIDE Y AND CORTICOTROPIN RELEASING FACTOR MODULATORS; DIETETICS; ANTIDIABETIC, ANTIINFLAMMATORY, AND ANTITUMOR AGENTS | AMGEN INC. | 2001-02-13 | — | — | US | disclosed |
| EP-1054887-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999040091-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | KCNJ1, KCNJ2, TRPV1 | IKBKB 3670/4885CHUK 2791/4885CYP1A2 2601/4885 |
| US-20040198742-A1 | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use | SLC5A2, TXNRD2, SLC5A1 | IKBKB 1750/4885CHUK 892/4885CYP1A2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.